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Abstract
 
Sepsis and meningitis caused by serogroup B meningococcus are devastating diseases of infants
and young adults, which cannot yet be prevented by vaccination. By genome mining, we dis-
covered GNA1870, a new surface-exposed lipoprotein of 
 
Neisseria meningitidis
 
 that induces
high levels of bactericidal antibodies. The antigen is expressed by all strains of 
 
N. meningitidis
 
tested. Sequencing of the gene in 71 strains representative of the genetic and geographic diver-
sity of the 
 
N. meningitidis
 
 population, showed that the protein can be divided into three vari-
ants. Conservation within each variant ranges between 91.6 to 100%, while between the vari-
ants the conservation can be as low as 62.8%. The level of expression varies between strains,
which can be classified as high, intermediate, and low expressors. Antibodies against a recombi-
nant form of the protein elicit complement-mediated killing of the strains that carry the same
variant and induce passive protection in the infant rat model. Bactericidal titers are highest
against those strains expressing high yields of the protein; however, even the very low expressors
are efficiently killed. The novel antigen is a top candidate for the development of a new vaccine
against meningococcus.
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Introduction
 
Neisseria meningitidis
 
 is a gram negative, encapsulated bacte-
rium which at any time colonizes the upper respiratory
 
tract of 
 
 
 
10% of human population. Colonizing strains
belong to hypervirulent lineages and carriage strains, which
are frequently or rarely associated with disease, respec-
tively. During nonepidemic periods approximately once in
every 10,000 colonized people or once in 100,000 popula-
tion, the bacterium enters the blood stream where it multi-
plies and gives sepsis. During epidemic periods, the attack
rates can be much higher. From the blood stream the bac-
terium may cross the blood-brain barrier and cause menin-
gitis. Both diseases are devastating and can kill 5–15% of
the affected children and young adults within hours, de-
spite the availability of effective antibiotics (1). Up to 25%
of those who survive are left with permanent sequelae,
which may include amputation of limbs, mental retarda-
tion, and hearing loss (2, 3). The bacteria have been classi-
fied in serogroups based on the chemical composition of
the polysaccharide capsule (4). Although 13 chemically
different serogroups have been described, only serogroups
A, B, C, Y, and W-135, and to a very minor extent X and
Z, have been associated with disease (5, 6). In addition to
the capsular serogroup, most of the meningococcal strains
isolated from invasive disease, have been classified by mul-
tilocus enzyme electrophoresis (MLEE) into a small num-
ber of hypervirulent lineages: Electrophoretic Types ET-37,
ET-5, cluster A4, lineage 3, subgroups I, III, and IV-1 (7,
8). Recently, a new sequence-based classification, multilo-
cus sequence typing (MLST) has been introduced, which
classifies the above strains mainly into Sequence Types
ST11, ST32, ST8, ST41, ST1, ST5, ST4, respectively (9).
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Carrier strains have a more diverse clustering, and a wider
range of genotypes.
Prevention of disease can effectively be accomplished by
vaccination. Immunization was made possible in 1969
when it was discovered that protection from disease corre-
lates with the presence in the serum of antibodies able to
induce complement-mediated killing of bacteria, and that
purified capsular polysaccharide was able to induce them.
Tetravalent vaccines against serogroups A, C, W-135, and
Y have been available since 1984 (10–12). Although effec-
tive in adults, polysaccharide vaccines are less efficacious in
infants and young children and do not induce immunologi-
cal memory, so that they have not been used for universal
vaccination. Recently, conjugate vaccines against serogroup
C have been introduced in the UK, Ireland, and Canada
(13, 14). These are immunogenic in infants and children,
induce immunological memory and show overall efficacy
of more than 90%. Tetravalent conjugate vaccines against
serogroups A, C, W-135, and Y are presently in clinical de-
velopment (15). As a consequence, during the next 4–6 yr
we expect to be able to prevent diseases caused by sero-
groups A, C, W-135, and Y in all age groups. Unfortu-
nately, the conjugate approach cannot be easily applied to
serogroup B because the capsular polysaccharide is a poly-
mer of 
 
 
 
(2
 
→
 
8)
 
N
 
-acetyl neuraminic acid or polysialic acid,
a molecule which is identical to a widely distributed human
carbohydrate. Being the serogroup B polysaccharide identi-
cal to a self-antigen, man is immunologically tolerant to it
and therefore fails to induce an effective immune response.
On the other hand, an immune response against it would
risk to induce autoimmunity (16, 17). For this reason, there
are no licensed vaccines available in the USA and Europe
for the prevention of serogroup B 
 
N. meningitidis
 
 disease,
which is responsible for 32% of all meningococcal disease in
the United States, for 45 to 80% of the cases in Europe and
for more than 50% of the cases in the rest of the world,
with the exception of Sub-Saharan Africa where serogroup
A is responsible for 90% of the cases (18, 19). To develop a
vaccine against serogroup B, surface-exposed proteins con-
tained in outer membrane vesicles (OMVs)
 
*
 
 have been
used (20, 21). These vaccines elicit serum bactericidal anti-
body responses and protect against meningococcal disease
(22, 23). However, while they induce complement-medi-
ated bactericidal antibodies against the homologous strain,
they fail to induce bactericidal antibodies against heterolo-
gous strains (24). For this reason their use has been limited
only to Central and South America.
In the year 2000 our laboratory published the use of the
genomic sequence of MC58 to discover novel antigens ca-
pable of inducing protection against serogroup B 
 
N. menin-
gitidis
 
 (25). Here we describe a novel antigen which was
discovered by mining the bacterial genome and that is very
effective in inducing bactericidal antibodies. This antigen is
a very good candidate for inclusion in universal vaccines
against 
 
N. meningitidis.
 
Materials and Methods
 
Strains. Escherichia coli
 
 DH5
 
 
 
 and BL21(DE
 
3
 
) were used as
cloning strain and expression host, respectively, and used as rec-
ommended by the manufacturer (Invitrogen).
 
N. meningitidis
 
 strains used were described by Comanducci et
al. (26). Selection was made to represent the meningococcal di-
versity both in terms of genotype and geographic distribution
(they derive from 19 different countries and 73% belong to sero-
group B). 32/71 (45%) were isolated during the last five years.
Most data in this paper refer to strains: MC58, 961–5945, M1239,
67/00, NZ394/98, H44/76, Cu385, (26), and 4243 (27). The
NZ394/98 strain was originally described by Diana Martin as
NZ98/254 (Institute of Environmental Science & Research Lim-
ited, Kenepuru Science Centre, Porirua, New Zealand).
 
GNA1870 Cloning, Expression, and Purification in E. coli.
gna1870
 
 genes
 
 
 
were amplified by PCR from the genome of 
 
N.
meningitidis
 
 MC58, 961–5945 and M1239 strains, respectively.
Forward and reverse primers were designed in order to amplify
the 
 
gna1870
 
 coding sequence devoid of the sequence coding for
the putative leader peptide. M1239 and 961–5945 variants were
found not to be expressible in 
 
E. coli
 
. Therefore, they were ex-
pressed by adding to the NH
 
2
 
-terminal the sequence GPDS-
DRLQQRRG that is present in the gonococcus protein, but ab-
sent in the meningococcus counterpart. Oligonucleotides used
for the amplification are reported as follows: strain MC58 (For1:
CGCGGATCCCATATGGTCGCCGCCGACATCG; Rev1:
CCCGCTCGAGTTGCTTGGCGGCAAGGC). strain 961–
5945(For2: CGCGGATCCCATATG
 
GGCCCTGATTCTGA-
CCGCCTGCAGCAGCGGAGG
 
GTCGCCGCCGACATC-
GG
 
; Rev2:CCCGCTCGAGCTGTTTGCCGGCGATGCC);
strain M1239 (For 2; Rev3:GCCCAAGCTTCTGTTTGCCG-
GCGATGCC).
Restriction sites, corresponding to NdeI for the forward primers
and XhoI for the reverse primers, are underlined. In the case of
M1239 strain the restriction site used for the reverse primer is Hind
III. For the 961–5945 and M1239 forward primers, the gonococ-
cus sequence moiety is reported in italics, whereas the meningo-
coccal GNA1870 matching sequences are reported in bold.
PCR conditions in the case of primer combination For1/
Rev1 were: denaturation at 94
 
 
 
C for 30 s, annealing at 57
 
 
 
C for
30 s, elongation at 68
 
 
 
C for 1 min (5 cycles), denaturation at
94
 
 
 
C for 30 s, annealing at 68
 
 
 
C for 30 s, elongation at 68
 
 
 
C for
1 min (30 cycles). In the case of primer combinations: For2/
Rev2, For3/Rev2, and For3/Rev3: 94
 
 
 
C for 30 s, 56
 
 
 
C for 30 s,
68
 
 
 
C for 1 min (5 cycles), 94
 
 
 
C for 30 s, 71
 
 
 
C for 30 s, 68
 
 
 
C for
1 min (30 cycles).
 
gna1870
 
 full-length gene was amplified from the MC58 ge-
nome using the following primers: f-lFor (CGCGGATC-
CCATATGAATCGAACTGCCTTCTGCTGCC) and f-lRev
(CCCGCTCGAGTTATTGCTTGGCGGCAAGGC) and the
following conditions: 94
 
 
 
C for 30 s, 58
 
 
 
C for 30 s, 72
 
 
 
C for 1
min (30 cycles).
PCR were performed on 
 
 
 
10 ng of chromosomal DNA using
High Fidelity Taq DNA Polymerase (Invitrogen). The pCR
products were digested with NdeI and XhoI and cloned into the
NdeI/XhoI sites of the pET-21b
 
 
 
 expression vector (Novagen).
Recombinant proteins were expressed as His-tag fusions and
purified by MCAC (Metal Chelating Affinity Chromatography),
as described previously (25).
 
gna1870 Gene Sequencing. gna1870
 
 gene was amplified using
primers external to the coding sequence (A1: GACCTGCCT-
CATTGATG and B2: CGGTAAATTATCGTGTTCG-
GACGGC). About 10 ng of chromosomal DNA were used as
 
*
 
Abbreviation used in this paper:
 
 OMV, outer membrane vesicle. T
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template for the amplification. PCR conditions were: 30 cycles,
94
 
 
 
C for 40 s, 58
 
 
 
C for 40 s, 68
 
 
 
C for 40 s. PCR fragment were
purified by the QIAGEN QIAquick PCR Purification Kit, and
submitted to sequence analysis, which was performed using an
ABI 377 Automatic Sequencer. The sequence was performed
using primers A1, B2, 22 (CAAATCGAAGTGGACGGG-
CAG), and 32 (TGTTCGATTTTGCCGTTTCCCTG). Se-
quence analysis was performed using Editview, GeneJockey,
MacBoxshade.
 
Computer Analysis.
 
The GCG Wisconsin Package suite (ver-
sion 10.0) was used for computer analysis of gene and protein se-
quences. The PSORT program (28) was used for localization
prediction. For secondary structure analysis, the PredictProtein
software available on the web at http://cubic.bioc.columbia.edu/
predictprotein/ was applied. The PSI-BLAST algorithm was used
for homology searches (http://www.ncbi.nlm.nih.gov/blast) us-
ing the nonredundant protein database. The prediction of the Fur
box was performed with FindPatterns (GCG) starting from the 
 
E.
coli
 
 consensus (29) and allowing a maximum of nine mismatches.
Search for lipoproteins with a glycine-rich region has been per-
formed on 22 complete genomic sequences retrieved at the
NCBI site (http://www.ncbi.nlm.nih.gov/PMGifs/Genomes/
micr.html) using FindPatterns. The complete genome sequence
of 
 
Neisseria gonorrhoeae
 
 strain FA1090 is available at the site http://
dna1.chem.ou.edu/gono.html.
The dendrograms were obtained starting from the multiple se-
quence alignment of GNA1870 protein sequences (PileUP) using
the Protein Sequence Parsimony Method (ProtPars), a program
available within the Phylogeny Inference Package (Phylip)
(Felsenstein, J. 1993, program distributed by the author), and
confirmed by the GCG program Distances, using the Kimura and
Jukes-Cantor algorithms.
 
gna1870 and siaD Isogenic Mutants.
 
Isogenic knockout mu-
tants in which the 
 
gna1870
 
 gene was truncated and replaced with
an erythromycin antibiotic cassette, was prepared by transform-
ing strains MC58, 961–5945 and M1239 with the plasmid
pBS
 
 
 
gna1870
 
ERM. This plasmid contains the erythromycin resis-
tance gene within the 
 
gna1870
 
 upstream and downstream flanking
regions of 500 bp. These regions were amplified from MC58 ge-
nome using the following oligonucleotides UFor-GCTCTA-
GACCAGCCAGGCGCATAC (Xba1 site underlined); URev
TCCCCCGGGGACGGCATTTTGTTTACAGG (Sma1 site
underlined); DFor TCCCCCGGGCGCCAAGCAATAAC-
CATTG (Sma1 site underlined) and DRev CCCGCTCGAG-
CAGCGTATCGAACCATGC (Xho1 site underlined). A cap-
sule-deficient mutant was generated using the same approach. The
 
siaD
 
 gene was deleted and replaced with 
 
ermC
 
 using the plasmid
pBS
 
 
 
Cap
 
ERM. The upstream and downstream flanking regions
of 1,000 bp and 1,056 bp, respectively, were amplified from
MC58 genome using the following primers: UCapFor GCTCTA-
GATTCTTTCCCAAGAACTCTC (Xba1 site underlined);
UcapRev TCCCCCGGGCCCGTATCATCCACCAC (Sma1 site
underlined); DCapFor TCCCCCGGGATCCACGCAAAT-
ACCCC (
 
Sma
 
1 site underlined) and DCapRev CCCGCTC-
GAGATATAAGTGGAAGACGGA (Xho1 site underlined). Am-
plified fragments were cloned into pBluescript and transformed
into naturally competent 
 
N. meningitidis
 
 strain MC58. The mixture
was spotted onto a GC agar plate, incubated for 6 h at 37
 
 
 
C, 5%
CO
 
2
 
, then diluted in PBS and spread on GC agar plates containing
5 
 
 
 
g/ml erythromycin. The deletion of the 
 
gna1870
 
 gene in the
MC58
 
 
 
gna1870
 
, 961–5945
 
 
 
gna1870
 
, and M1239
 
 
 
gna1870
 
strains was confirmed by PCR; lack of GNA1870 expression was
confirmed by Western blot analysis. The deletion of the 
 
siaD
 
 gene
 
and the lack of capsule expression in the MC58
 
 
 
siaD
 
 strain were
confirmed by PCR and FACS
 
®
 
, respectively.
 
Expression of GNA1870 during Growth.
 
MC58 strain was
grown at 37
 
 
 
C with 5% CO
 
2
 
 in GC medium at stationary phase.
Samples were collected during growth (OD
 
620
 
 of 0.05–0.9).
MC58
 
 
 
gna1870
 
 was grown until the OD
 
620
 
 of 0.5. Bacterial cells
were collected by centrifugation, washed once with PBS, and re-
suspended in various volumes of PBS in order to standardize the
OD values. Culture supernatant was filtered using a 0.2 
 
 
 
m filter
and 1 ml precipitated by the addition of 250 
 
 
 
l of 50% trichloro-
acetic acid (TCA). The sample was incubated on ice for 2 h, cen-
trifuged for 40 min at 4
 
 
 
C and the pellet washed with 70% ice
cold ethanol, and resuspended in PBS. 3 
 
 
 
l of each sample (cor-
responding to an OD
 
620
 
 of 0.03) was then loaded on a 12% poly-
acrylamide gels and electrotransferred onto nitrocellulose mem-
branes. Western blot analysis was performed according to
standard procedures (30), using anti-GNA1870 polyclonal anti-
bodies at a 1:1,000 dilution, followed by a 1:2,000 dilution of
HPR-labeled anti-human IgG (Sigma-Aldrich). Scanning was
performed using a LabScan (Amersham Biosciences) and Image-
master software (Amersham Biosciences).
 
 [
 
3
 
H]-palmitic Acid Labeling of E. coli and N. meningitidis.
 
Palmitate incorporation of recombinant 
 
E. coli
 
 BL21(DE3) strain
carrying the full-length 
 
gna1870
 
 gene was confirmed as described
by Jennings et al. (31).
Meningococcal strains MC58 and MC58
 
 
 
gna1870
 
 were
grown in GC medium and labeled with [9,10-
 
3
 
H]-palmitic acid
(Amersham Biosciences). Cells from 5 ml culture were lysed by
boiling for 10 min and centrifuged at 13,000 rpm. The superna-
tants were precipitated with TCA and washed twice with cold
acetone. Proteins were suspended in 50 
 
 
 
l of 1.0% SDS and 15
 l analyzed by SDS-PAGE, stained with Coomassie brilliant
blue, fixed, and soaked for 15 min in Amplify solution (Amer-
sham Biosciences). Gels were exposed to Hyperfilm MP (Amer-
sham Biosciences) at –80 C for 3 d.
Binding Assay to Human Transferrin. Recombinant GNA1870,
human transferrin hTF (Sigma T-4132) and the mix of the two
(final concentration of 7  M) were dialysed O/N in PBS at 4 C.
After dialysis 20  l of each protein and the mixture of them were
loaded on a HPLC Superdex 200 PC 3.2/30 gel filtration column
(Amersham Biosciences) using PBS as running buffer (32). Blue
Dextran 2000 and the molecular weight standards ribonuclease A,
chymotrypsinogen A, ovalbumin, bovine serum albumin (Amer-
sham Biosciences) were used to calibrate the column. Gel filtra-
tion was performed using a Smart system with a flow rate of 0.04
ml/min and the eluted material monitored at 214 and 280 nm
(the GNA1870 retention volume was 1.68 ml and 1.47 ml for
htf). Fractions of 40  l were collected and analyzed by SDS-
PAGE. The MC58 recombinant transferrin-binding protein 2
(Tbp2) was used as positive control.
Mice Immunizations. To prepare antisera, 20  g of variant 1,
variant 2, and variant 3 GNA1870 recombinant proteins were
used to immunize 6-wk-old CD1 female mice (Charles River
Laboratories). Four to six mice per group were used. The recom-
binant proteins were given intraperitoneally, together with CFA
for the first dose and IFA for the second (day 21) and third (day
35) booster doses. The same immunization schedule were per-
formed using Aluminium hydroxide (3 mg/ml) instead of Freund’s
adjuvant. Blood samples for analysis were taken on day 49.
FACS® Analysis. The ability of polyclonal anti-GNA1870
antisera to bind to the surface of live meningococci was deter-
mined using FACScan™ flow cytometer on the MC58,
MC58 siaD (nonencapsulated) and MC58 gna1870, on 961–T
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5945 and 961–5945 gna1870, on M1239 and M1239 gna1870,
on NZ394/98 and 67/00 strains. Antibody binding was de-
tected using a secondary antibody anti–mouse (whole molecule)
FITC-conjugated (Sigma-Aldrich). The positive control in-
cluded SEAM 3, a mAb specific for the meningococcus B cap-
sular polysaccharide (33). The negative control consisted of a
mouse polyclonal antiserum against the cytoplasmic protein
NMB1380 (34).
Complement-mediated Bactericidal Activity. Serum bactericidal
activity against N. meningitidis strains was evaluated as described
previously (25, 35), with pooled baby rabbit serum (CedarLane)
used as complement source. A human serum from an healthy
adult (with no intrinsic bactericidal activity when tested at a final
concentration of 25 or 50%) was also used as complement source.
Serum bactericidal titers were defined as the serum dilution re-
sulting in 50% decrease in CFU per ml after 60 min incubation of
bacteria with reaction mixture, compared with control CFU per
ml at time 0. Typically, bacteria incubated with the negative con-
trol antibody in the presence of complement showed a 150 to
200% increase in CFU/ml during the 60 min incubation.
Western Blot Analysis on Human Sera. Purified GNA1870 (1
 g/lane) was loaded onto 12.5% SDS-polyacrylamide gels and
transferred to a nitrocellulose membrane. The bound protein was
detected with 1:200 dilution of convalescent or normal sera, fol-
lowed by a 1:2,000 dilution of HPR-labeled anti–human IgG
(Sigma-Aldrich).
Rat Protection. 5-d-old infant rats were pretreated intraperito-
neally with anti-GNA1870 antisera or with anti-PorA mono-
clonal antibody at time 0 and challenged 2 h later intraperitoneally
with 1.9   103 CFU/rat of MenC 4243 (OAc-positive). Quanti-
tative blood cultures were obtained 18 h later. Bacterial counts in
the blood cultures were obtained by plating 100, 10, and 1  l (10
 l of a 1:10 dilution) of blood on chocolate agar plates.
Results
GNA1870 Gene and Protein Features. Genome-derived
Neisseria Antigen 1870 (GNA1870) was selected while
mining the still incomplete genome of the serogroup B
strain MC58, because it had the typical signature of a sur-
face-exposed lipoprotein. This was characterized by a signal
peptide with a lipo-box motif of the type –Leu-X-X-Cys,
where the Cysteine was followed by a Serine, an amino
acid generally associated with outer membrane localization
of lipoproteins (36). The gene was annotated as nmb1870
and nma0586 in the genome sequences of MenB MC58
and MenA Z2491 published by The Institute for Genomic
Research (TIGR) and Sanger Center, respectively (37, 38).
Interestingly, the electronic annotation of TIGR and
Sanger assigned the gene start to ATG sequences located
138 and 18 base pairs upstream from the GTG that we pro-
pose as the real start codon. This new position is consistent
with the presence of a correctly spaced ribosome-binding
site, as well as with the prediction of the lipoprotein signa-
ture (Fig. 1).
According to our analysis, gna1870 is a monocistronic
gene and is located 157 bases downstream the stop codon
of the fructose-bisphosphate aldolase gene nmb1869 (Fig.
1). In MenA Z2491 the overall organization is similar,
however, 31 base pairs upstream from the GTG starting
codon there is an insertion of 186 nucleotides that are ho-
mologous to an internal repeat region of IS1106, and are
flanked by two 16 base pairs inverted repeats. A putative ri-
bosome binding site and a putative Fur box are present 8
and 35 bp, respectively, upstream from the GTG starting
codon. Putative promoter sequences were also detected.
The mature protein is predicted to be a lipoprotein with a
molecular weight of 26,964 Daltons and an isoelectric
point of 7.96 in MC58, and is characterized by the pres-
ence of four Glycines downstream of the lipo-box motif.
Secondary structure prediction analysis indicates that
GNA1870 is a globular protein mostly composed of  
sheets. No homologous proteins were found by searching
existing nonredundant prokaryotic and eukaryotic protein
databases maintained at the NCBI site, including the hu-
man genome, suggesting that this protein is specific for
Neisseria. However, a domain with some homology (28%
identity over 146 amino acids) was found with the
COOH-terminal portion of the transferrin-binding protein
Figure 1. Nucleotide se-
quence of the region upstream
gene  gna1870 in MenB strain
MC58. The DNA and deduced
amino acid translation of the
GNA1870 predicted lipoprotein
signal peptide are also shown.
The translation initiation codon
GTG is positioned at nucleotide
 1. The putative ribosome
binding site (RBS) is shaded and
two possible –10 and –35 pro-
moter elements are indicated by
dashed lines and dots, respec-
tively. A putative Fur box is in-
dicated (the sequence CAT-
AACCAAAATGTTTATA matches the E. coli Fur box consensus GATAATGATAATCATTATC in 11 over 19 bases). Horizontal arrows indicate two
inverted repeats containing a DNA uptake sequence. The start codons attributed by TIGR and Sanger are indicated by a box and a circle, respectively.
The pentanucleotide ATATT used as site of insertion for the IS fragment in MenA strain Z2491 is underlined. In MenA, the presence of the IS fragment
creates novel –10 and –35 elements. In Gonococcus, the whole region is conserved with that of MenB, however, the insertion of a single base (G) after
position 36 causes a frame-shift, which results in the loss of the lipo-box motif. The correct frame is reestablished with a further eight-base insertion after
position 73.T
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TfbA of Actinobacillus pleuropneumoniae (39). This amino
acid homology does not seem to reflect a functional ho-
mology since the recombinant protein failed to bind hu-
man transferrin in vitro (data not depicted).
Protein Expression and Lipidation. To produce a recom-
binant GNA1870, either the full-length gene or the region
coding for amino acids 8–255 were amplified from N. men-
ingitidis strain MC58 by PCR and cloned in the expression
vector pET21b . The recombinant COOH-terminal His-
tagged fusion protein was purified and used to immunize
mice to obtain antisera. When the full-length clone was
grown in the presence of [9,10-3H]-palmitic acid, a radio-
active band was detected at the expected molecular weight,
confirming that E. coli recognizes the lipoprotein motif and
adds a lipid tail to the recombinant protein (data not de-
picted). A radioactive band of the appropriate molecular
weight was also detected in N. meningitidis grown in the
presence of [9,10-3H]-palmitic acid (data not depicted).
We conclude that GNA1870 is a lipoprotein both in N.
meningitidis and in E. coli. The lipoprotein is surface-exposed
and expressed at different levels by different strains.
Immune sera raised against the recombinant protein
were used to detect the lipoprotein in N. meningitidis
MC58 by Western blotting and FACS®. As shown in Fig.
2, a protein of  29.5 kD was detected in the total cell ex-
tracts of N. meningitidis. Scanning of the Western blot in
Fig. 2 A showed that the amount of the protein in the
whole cell lysate increased approximately two times dur-
ing the growth curve, while the optical density of the cul-
ture increased from 0.05 to 0.9 OD620nm. Interestingly, a
band of the same size was also detected in the culture su-
pernatant. The protein was not detected in the supernatant
of the freshly inoculated culture (OD620nm of 0.05), and in-
creased approximately four times during the growth from
0.1 to 0.9 OD620nm (Fig. 2 B, insert 1). The genuine nature
of the supernatant was confirmed by testing the same sam-
ples for the absence of membrane blebs and of cytoplasmic
proteins. As shown in Fig. 2 B, insert 2, the absence in the
supernatant preparations of PorA, known to be a major
component of membrane blebs, rules out a possible con-
tamination with membrane blebs, while the absence in the
supernatant of the cytoplasmic protein NMB1380 con-
firmed that the supernatant samples do not result from cell
lysis (Fig. 2 B, insert 3). The MC58 gna1870 strain,
where the gene coding for the protein GNA1870 had
been deleted, shows no protein either in the whole cell ly-
sate or in the culture supernatant (KO lane, in Fig. 2, A
and B). The protein was detected by Western blotting in
outer membrane vesicles vaccines prepared by the Norwe-
gian Institute of Public Health (NIPH), confirming that
the protein segregates with the membrane fractions of N.
meningitidis (Fig. 2 C). Interestingly, sera from mice immu-
nized with the NIPH vaccine did not recognize the re-
combinant GNA1870 in Western blotting (data not
shown), suggesting that the protein is not immunogenic in
these preparations.
FACS® analysis confirmed that the protein is surface-
exposed and accessible to antibodies both in encapsulated
and nonencapsulated N. meningitidis strains (Fig. 2 D). West-
ern blotting analysis of 43 strains showed that the protein was
expressed by all strains tested. However, as shown in Fig. 3,
the levels of expression varied considerably from strain to
Figure 2. Expression of GNA-
1870 in strain MC58. (A and insert 1
of B) Western blots of whole cell
lysates and culture supernatants,
respectively. Cultures were har-
vested at different times during the
growth curve and probed with the
anti-GNA1870 serum. (B, inserts 2
and 3) Culture supernatants probed
with anti-PorA and anti-NMB1380
antisera, respectively. The OD620 of
the culture is indicated above each
lane. KO indicates a gna1870 knock-
out mutant of MC58. Wcl stands for
whole cell lysate used as control. (C)
Outer membrane vesicle (OMV)
vaccine from the Norwegian Insti-
tute of Public Health and recombi-
nant GNA1870 used as positive con-
trol probed with anti-GNA1870
serum. (D) FACS® analysis of encap-
sulated MC58 and of its nonencap-
sulated isogenic mutant using the
serum against GNA1870. Shaded
profile is the negative control ob-
tained by reaction with the preim-
mune serum. Non-shaded profile
shows reaction with immune sera.T
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strain. The strains tested could be broadly classified as high,
intermediate, and low expressors. Scanning of the Western
blots showed that the difference in expression between
high and intermediate, intermediate and low or high and
low could be two-, five-, and ninefold, respectively. As
shown in Table I, of the 43 strains tested, 25 (58%) ex-
pressed high levels of GNA1870, 11 (25.5%) expressed in-
termediate levels, and 7 (16.5%) expressed low levels. Most
of the strains from hypervirulent lineages (ET-5, lineage 3,
and ET-37) expressed high levels of the protein, with the
exception of A4 isolates where two strains expressed inter-
mediate levels and two expressed low levels. Interestingly,
the protein was expressed at high level by strains that have
been classically used as OMV vaccine strains (H44/76 and
Cu385). No obvious genetic patterns were found to pre-
dict the amount of protein expressed by each strain. Even
the presence of the IS element in the promoter region,
which was found in 8/71 strains (one from serogroup A,
three from lineage 3, and four from those classified as oth-
ers), did not show any correlation with the expression of
the protein.
21/40 convalescent sera recognized the recombinant pro-
tein in Western blot, while only 2/10 of sera from healthy
people recognized it. Thus, GNA1870 may be immuno-
genic in patients recovering from meningococcal disease.
The Protein Induces Bactericidal Antibodies and Confers Pas-
sive Protection in the Infant Rat. The antisera obtained im-
munizing with the recombinant protein were tested for
their ability to induce complement-mediated killing of en-
capsulated  N. meningitidis strains. Representative strains
from the high, intermediate and low expressors were se-
lected for the assay using Western blotting. The differential
expression of the protein on the surface of the selected
strains was confirmed by FACS® analysis (Fig. 4). As shown
in the figure, MC58, a representative of the high expressor
strains was killed with high efficiency by the serum diluted
up to 1/64,000, NZ394/98, a representative of the inter-
mediate expressors was also killed with high efficiency, by
the serum diluted up to 1/16,000 and even strain 67/00, a
representative of the low expressor strains was killed by the
antiserum diluted up to 1/2,048. A control strain, where
the gna1870 gene had been knocked out, was not killed by
the same antiserum. To determine whether the sera were
also able to confer protection in vivo, we tested them for
their ability to induce passive protection in the infant rat
model using two serogroup B and one serogroup C strains.
Protection was achieved with all strains and the results ob-
tained with one of the strains are shown in Table II. No
bacterial colonies were recovered from the blood of the rats
passively immunized with the anti GNA1870, while most
of the controls were bacteremic. Similar results were ob-
tained with two other strains (data not shown).
Gene Distribution and Protein Diversity. gna1870 gene
was detected by PCR in 71/71 Neisseria strains. The strain
panel mostly includes serogroup B strains, a few strains of
serogroups A, C, Y, W-135, and Z, and one strain each of
N. gonorrhoeae and N. cinerea. In N. lactamica we could de-
tect a band by Western blotting, but we failed to amplify
the gene. Nucleotide sequence of the gene was determined
in all 71 strains. Computer analysis of the gna1870 encoded
peptides, using Kimura and Jukes-Cantor algorithm di-
vided the family in three variants (Fig. 5). Strains MC58,
961–5945, and M1239 were arbitrarily selected as type
Figure 3. Western blots of a gradient SDS-PAGE gel loaded with total
cell lysates of strains expressing high (lanes 1 and 2), intermediate (lanes 3
and 4), and low (lanes 5 and 6) levels of GNA1870. Lane 7 contains a to-
tal cell lysate from strain MC58 in which the gene encoding GNA1870
has been inactivated. Lane 1 strain MC58; lane 2 strain H44/76; lane 3
strain NZ394/98; lane 4 strain 961–5945, lane 5 strain 67/00, lane 6
strain M1239, lane 7 MC58 gna1870.
Table I. Level of Expression of GNA1870
Strains High Intermediate Low
ET-5 9/9 0/9 0/9
Lineage 3 7/9 1/9 1/9
ET-37 2/3 1/3 0/3
A4 0/4 2/4 2/4
Other 6/15 7/15 2/15
N. gonorrhoeae 0/1 0/1 1/1
N. cinerea 0/1 0/1 1/1
N. lactamica 1/1 0/1 0/1
Total 25/43 (58%) 11/43 (25.5%) 7/43 (16.5%)
Figure 4. Bactericidal activity and FACS® analysis results of three
strains expressing high, intermediate or low levels of GNA1870, based on
Western blot of whole-cell lysates with antiserum against GNA1870.
Shaded profiles are the negative controls obtained by reaction with the
preimmune sera; nonshaded profiles show binding of immune sera. The
intermediate expressor NZ394/98 and the low expressor 67/00 have
identical amino acid sequences, which are 91.6% homologous to MC58.T
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strains for variants 1, 2, and 3, respectively. The sequence
diversity between the three type strains is shown in Fig. 6.
Amino acid identity was 74.1% between variant 1 and vari-
ant 2, 62.8% between variant 1 and variant 3, and 84.7%
between variant 2 and variant 3. Sequences within each
variant were well-conserved, the most distant showing
91.6, 93.4, and 93.2% identity to their type strains, respec-
tively. N. cinerea belongs to variant 1, and shares 96.7% ho-
mology with MC58. As shown in Fig. 5, variant 1 harbors
all strains from hypervirulent lineages ET-5, most lineage 3
strains, the serogroup A strains, two recent isolates of
W-135 and one ET-37 strain. Variant 2 harbors all strains
from the hypervirulent complex A4, from serogroups Y
and Z, one old W-135 isolate and four ET-37 strains. Vari-
ant 3 harbors four unique ST strains, one ET-37 strain, one
lineage 3 strain, and gonococcus.
Bactericidal Activity is Variant-specific. One sequence of
each variant was expressed in E. coli as His-tag and used to
immunize mice. The resulting antisera were used to test
immunological cross-reactivity between strains of the three
variants by FACS® and bactericidal assay. As shown in Fig.
7, by FACS® analysis, all strains were recognized by each
antiserum, however, the degree of recognition varied con-
siderably, usually reflecting the amino acid homology be-
tween the proteins. In fact, the antiserum against the vari-
ant 1 protein (Fig. 7, first row) recognized very well the
MC58 strain, to a lower extent the 961–5945 strain, which
is 74.1% homologous and, to a lesser extent, the strain
M1239 that has an amino acid identity of 62.8%. A similar
trend was found for antisera against variants 2 and 3 (rows 2
and 3, respectively, of Fig. 7), although with the anti vari-
ant 2 serum the differences were not striking. A mono-
clonal antibody against the capsule recognized equally well
the three strains (Fig. 7, row 4), while a serum against the
cytoplasmic protein NMB1380 used as negative control did
not recognize them (Fig. 7, row 5). The gna1870 knock-
out mutants were not recognized at all by their specific sera
(Fig. 7, row 6).
The differences in immuno-recognition between the
three variants were more evident by bactericidal assay. As
shown in Table III, the serum against each variant was able
to induce efficient complement-mediated killing of the
homologous strain (titers ranging between 16,000 and
64,000), while the activity was low (titers of 128–2,048) or
absent (titers  4) against strains of the other variants.
Moreover, in the case of variant 1, we also showed that the
most distantly related strains, located at the bottom of the
dendogram in Fig. 5, were killed by the anti-MC58 antise-
rum (titers of above 2.048).
As predicted from the close amino acid homology, the
cross-bactericidal titers between variants 2 and 3 were
higher than the others. When human complement was
used, bactericidal titers of 4,096, 256 and 512 were ob-
tained with variants 1, 2, and 3, respectively, using the ho-
mologous strains of Table III. No titers were detected
against the heterologous strains.
Discussion
Vaccination against N. meningitidis serogroups A, C,
W-135, and Y is likely to enter routine use once the con-
jugate vaccines against these strains will complete the ongo-
ing clinical trials. This will leave disease caused by serogroup
B meningococcus, which causes  50% of invasive disease as
the only one not preventable by vaccination. Given the
chemical composition of the serogroup B capsule, which is
identical to a polysaccharide present in human tissues, devel-
opment of universal protein-based vaccines against sero-
group B N. meningitidis are desirable and urgent.
Conventional approaches to protein-based vaccine de-
velopment have delivered OMV vaccines which, although
Table II. Passive Protection of Infant Rats Challenged with 5   
107 CFU of Serogroup C Strain 4243
Pretreatment
Dose of Ab
(100  l per rat)
or
serum dilution
No.
bacteremia/total
CFU/ml
(geometric
mean)
PBS – 5/5 450,000
Neg. control serum 1:10 5/5 500,000
Anti-PorA
(mAb (P1.2)
2.0  g 1/5 3
Anti-GNA1870
1:10
1:50
0/5
0/4
 1
 1
Blood cultures were obtained 18 h after challenge.
Figure 5. Dendrogram showing the strain clustering according to
GNA1870 protein distances. 1, 2, and 3 indicate the three variants. Num-
bers in square brackets indicate the strains with identical sequence present
in each branch of the dendrogram. Hypervirulent lineages are indicated,
followed by the number of strains when this is different from the total
number. Serogroups other than B are also shown. The three type strains
(MC58, 961–5965, and M1239) and other strains used in the reported se-
rological analysis and infant rat studies are within circles.T
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efficacious against homologous strains, are unable to induce
complement-mediated bactericidal antibodies against het-
erologous strains, especially in infants and toddlers. The de-
termination of the genome sequence of group B strain
MC58 made available the entire repertoire of gene prod-
ucts and allowed the discovery of several novel antigens,
which may be used alone or in combination for the devel-
opment of new vaccines. Some of these were briefly de-
scribed in initial publications (25), while others have been
described in more detail (26, 40). Here we report the dis-
covery and characterization of a novel antigen, that is
present on the surface of all strains of N. meningitidis tested
and that is a highly promising candidate for the develop-
ment of protein-based vaccines against meningococcus.
GNA1870 May Be Sufficient to Immunize against Most
Strains of N. meningitidis. The observation that GNA1870
is expressed on the surface by all strains tested to date and is
a good target for bactericidal antibodies makes this protein
an excellent vaccine candidate. However, there are two
potential problems that may limit the possibility of using
the antigen. The first is that the expression varies from
strain to strain; the second is that there is sequence variabil-
ity with little or no cross-protection between the different
variants. Here we have shown that even strains expressing
Figure 6. Sequence align-
ment of variant 1 (strain MC58),
variant 2 (strain 961–5945), and
variant 3 (strain M1239). Amino
acid numbers initiate from the
Cysteine predicted to be the first
amino acid of the mature pro-
tein. Gray and black back-
grounds indicate conserved and
identical residues, respectively.
Figure 7. FACS® analysis of sera prepared against recombinant
GNA1870 protein representative of variant 1 (first row), variant 2 (second
row), and variant 3 (third row), using the type strain of variant 1 (MC58),
variant 2 (961–5945), and variant 3 (M1239). Control sera against the
capsular polysaccharide is shown in row 4 (monoclonal antibody Seam3).
A negative control antiserum against a cytoplasmic protein is shown in
row 5 (anti-NMB1380). Row 6 contains the knockout mutants (KO) of
each type strain, probed with the homologous antiserum. Shaded profile
are the negative controls obtained by reaction with the preimmune sera.
Non-shaded profiles show reaction with immune sera.T
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very low quantities of the protein are efficiently killed by
the antisera, a result suggesting that even the low expressors
have enough protein on the surface to be a target for com-
plement-mediated attack. The sequence diversity, on the
other hand, is limited to three variants, so that we believe it
should be possible to induce immunity against all strains of
meningococcus by immunizing with a combination of the
three proteins. Although our focus is the development of a
vaccine against meningococcus B, the data suggest that vac-
cination with three proteins would induce immunity
against all serogroups of meningococcus (see Table II, in-
fant rat protection using a C strain, 4243).
Features of the Gene and Protein. The presence of a puta-
tive Fur box in the promoter suggests that the expression of
GNA1870 may be regulated by iron. However, prelimi-
nary experiments have shown that the expression of the
protein does not increase in low iron conditions (data not
shown). We have not been able to find a reason for the dif-
ferent expression of the protein by different strains. Analysis
of the DNA sequences upstream from the gene did not
show any feature that we could correlate with the differen-
tial expression.
An interesting feature of the protein is the presence of a
stretch of four Glycines downstream from the lipidated
Cysteine. Three or more consecutive glycines downstream
from the lipidated Cysteine are present also in other five li-
poproteins in N. meningitidis, namely the transferrin-bind-
ing protein B (TbpB), the outer membrane component of
an ABC transporter NMB0623, the hypothetical protein
NMB1047, the TbpB homologue GNA2132 (25), and the
AspA lipoprotein (41). In none of these proteins is the
poly-glycine stretch encoded by a poly-G tract, suggesting
that this feature is not there to generate antigenic modula-
tion. Proteins with this signature are widespread in
prokaryotic organisms. A search performed on 22 complete
bacterial genomes retrieved 29 lipoproteins with this motif
in some but not all bacterial species. The organisms with
these type of lipoproteins include both gram negative and
gram positive bacteria such as Haemophilus influenzae, En-
terococcus fecalis, Mycobacterium tuberculosis, Listeria monocytoge-
nes, Staphylococcus aureus, while others such as E. coli, Bacil-
lus subtilis, Helicobacter pylori, Streptococcus pneumoniae, S.
pyogenes, and Vibrio cholerae have none. Most of the lipopro-
teins with this signature belong to ABC transporters, fol-
lowed by proteins of unknown function. Although this
common feature in the primary structure suggests a com-
mon role for the Glycine repeats, so far, the function is not
known. However, it has been recently proposed that it
may serve to guide the lipoproteins to a specific pathway of
secretion and surface localization (42).
Conclusions. We have described a new protein of N.
meningitidis, which is immunogenic during disease, is able
to induce bactericidal antibodies in mice, and whose result-
ing antibodies confer passive protection against meningo-
coccal bacteremia in infant rats. The protein is expressed by
all strains tested. Overall these data suggest that protection
against most N. meningitidis strains can be achieved by im-
munizing with three sequence variants of the protein. If
human trials with this protein will induce an immune re-
sponse similar to the one described here for mice, the de-
velopment of protein-based vaccines against meningococ-
cus may become a reality. In theory the three variants of
GNA1870 could be enough to elicit immunity against all
strains of meningococcus, however, a vaccine containing
also other antigens may be more appropriate, because it
would target more than one antigen per bacterium and
therefore it would decrease the possibility of selecting es-
cape mutants. A question that needs to be addressed in fu-
ture studies is whether vaccines based on common proteins
will immunize also against commensal Neisseria and
whether this is desirable.
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